We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > piroxicam

News List

Additional Positive Interim Results from Nanoform's Clinical Study prnasia
February 24, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
Nanoform's Clinical Study Indicates Positive Interim Results prnasia
January 22, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful.
Nanoformed formulation of piroxicam to enter Phase I trials europeanpharmaceuticalreview
October 23, 2020
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
Unichem Laboratories receives ANDA approval from US FDA for piroxicam caps financialexpress
April 18, 2017
Piroxicam is a non-steroidal anti-inflammatory drug indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis